FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129459102> ?p ?o ?g. }

• W2129459102 endingPage "5424" @default.
• W2129459102 startingPage "5418" @default.
• W2129459102 abstract "To determine the feasibility and a recommended phase II dose of tirapazamine when combined with chemoradiotherapy in limited-stage small cell lung cancer (LSCLC).Concurrent chemoradiotherapy consisted of two cycles of cisplatin, etoposide, and once-daily radiation to 61 Gy. Tirapazamine (260 mg/m2) was given 1 h before cisplatin with planned dose escalation to 330 mg/m2 in the absence of dose-limiting toxicity, defined as > or =33% esophagitis (grade 3 or above). Consolidation therapy consisted of two cycles of tirapazamine (330 mg/m2), cisplatin, and etoposide. Complete responders received prophylactic cranial irradiation.Thirty patients were enrolled at the 260 mg/m2 tirapazamine dose. All had performance status of 0-1. By comparison with S9713, a predecessor Southwest Oncology Group study in LSCLC that used the same concurrent chemoradiotherapy without tirapazamine, the present trial showed a higher rate of grade 3-4 esophagitis (34% versus 22%), vomiting (34% versus 23%), and febrile neutropenia (7% versus 2%). The consolidation phase was relatively well tolerated, with grade 4 neutropenia in 44% and febrile neutropenia in 5% of patients. There were two treatment-related deaths: one from neutropenic fever and one from respiratory infection. The overall response rate was 80%, and the median survival was 22 months.Protocol-defined dose-limiting toxicity was observed at the initial tirapazamine dose, precluding dose escalation. Compared with S9713, the addition of tirapazamine increased the incidence of vomiting, neutropenia, and febrile neutropenia, although the overall toxicity profile remained acceptable. In view of the observed favorable survival, further study of tirapazamine in LSCLC is warranted." @default.
• W2129459102 created "2016-06-24" @default.
• W2129459102 creator A5002905010 @default.
• W2129459102 creator A5012323508 @default.
• W2129459102 creator A5020320446 @default.
• W2129459102 creator A5027304240 @default.
• W2129459102 creator A5029123414 @default.
• W2129459102 creator A5036091074 @default.
• W2129459102 creator A5063441489 @default.
• W2129459102 creator A5064449830 @default.
• W2129459102 creator A5074848733 @default.
• W2129459102 creator A5085722656 @default.
• W2129459102 date "2004-08-15" @default.
• W2129459102 modified "2023-10-16" @default.
• W2129459102 title "Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004)" @default.
• W2129459102 cites W1868704956 @default.
• W2129459102 cites W1885320430 @default.
• W2129459102 cites W1905406155 @default.
• W2129459102 cites W1920090590 @default.
• W2129459102 cites W1935482218 @default.
• W2129459102 cites W193937562 @default.
• W2129459102 cites W1973865448 @default.
• W2129459102 cites W1979317247 @default.
• W2129459102 cites W1985883143 @default.
• W2129459102 cites W1986794774 @default.
• W2129459102 cites W1990497183 @default.
• W2129459102 cites W1997518044 @default.
• W2129459102 cites W2008347666 @default.
• W2129459102 cites W2010286218 @default.
• W2129459102 cites W2014017843 @default.
• W2129459102 cites W2018210528 @default.
• W2129459102 cites W2021907624 @default.
• W2129459102 cites W2036789410 @default.
• W2129459102 cites W2046155840 @default.
• W2129459102 cites W2046492464 @default.
• W2129459102 cites W2062410878 @default.
• W2129459102 cites W2064248272 @default.
• W2129459102 cites W2067686632 @default.
• W2129459102 cites W2084979429 @default.
• W2129459102 cites W2101038194 @default.
• W2129459102 cites W2105024669 @default.
• W2129459102 cites W2120826482 @default.
• W2129459102 cites W2139248078 @default.
• W2129459102 cites W2143124651 @default.
• W2129459102 cites W2153965661 @default.
• W2129459102 cites W2160012348 @default.
• W2129459102 cites W2160585366 @default.
• W2129459102 cites W2256738179 @default.
• W2129459102 cites W2271870719 @default.
• W2129459102 cites W2275341372 @default.
• W2129459102 cites W2323020638 @default.
• W2129459102 cites W2341745217 @default.
• W2129459102 doi "https://doi.org/10.1158/1078-0432.ccr-04-0436" @default.
• W2129459102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15328179" @default.
• W2129459102 hasPublicationYear "2004" @default.
• W2129459102 type Work @default.
• W2129459102 sameAs 2129459102 @default.
• W2129459102 citedByCount "36" @default.
• W2129459102 countsByYear W21294591022012 @default.
• W2129459102 countsByYear W21294591022013 @default.
• W2129459102 countsByYear W21294591022014 @default.
• W2129459102 countsByYear W21294591022015 @default.
• W2129459102 countsByYear W21294591022017 @default.
• W2129459102 countsByYear W21294591022018 @default.
• W2129459102 countsByYear W21294591022020 @default.
• W2129459102 countsByYear W21294591022021 @default.
• W2129459102 countsByYear W21294591022022 @default.
• W2129459102 countsByYear W21294591022023 @default.
• W2129459102 crossrefType "journal-article" @default.
• W2129459102 hasAuthorship W2129459102A5002905010 @default.
• W2129459102 hasAuthorship W2129459102A5012323508 @default.
• W2129459102 hasAuthorship W2129459102A5020320446 @default.
• W2129459102 hasAuthorship W2129459102A5027304240 @default.
• W2129459102 hasAuthorship W2129459102A5029123414 @default.
• W2129459102 hasAuthorship W2129459102A5036091074 @default.
• W2129459102 hasAuthorship W2129459102A5063441489 @default.
• W2129459102 hasAuthorship W2129459102A5064449830 @default.
• W2129459102 hasAuthorship W2129459102A5074848733 @default.
• W2129459102 hasAuthorship W2129459102A5085722656 @default.
• W2129459102 hasBestOaLocation W21294591021 @default.
• W2129459102 hasConcept C109316439 @default.
• W2129459102 hasConcept C126322002 @default.
• W2129459102 hasConcept C141071460 @default.
• W2129459102 hasConcept C185592680 @default.
• W2129459102 hasConcept C202751555 @default.
• W2129459102 hasConcept C2776313096 @default.
• W2129459102 hasConcept C2776694085 @default.
• W2129459102 hasConcept C2777063308 @default.
• W2129459102 hasConcept C2778119113 @default.
• W2129459102 hasConcept C2778424827 @default.
• W2129459102 hasConcept C2778850193 @default.
• W2129459102 hasConcept C31760486 @default.
• W2129459102 hasConcept C42219234 @default.
• W2129459102 hasConcept C509974204 @default.
• W2129459102 hasConcept C55493867 @default.
• W2129459102 hasConcept C71924100 @default.
• W2129459102 hasConcept C90924648 @default.
• W2129459102 hasConceptScore W2129459102C109316439 @default.

• next